Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Plan to “Institutionalize” Key Premium Ditched for FY2014 Revision; Status Quo to Remain
December 19, 2013
- Chuikyo Subcommittee Agrees on 60% Rule for First Generic Prices, 70% for Biosimilars
December 19, 2013
- Off-Patent Drugs to Get Continuous Price Cuts Until 60% Generic Share Reached
December 19, 2013
- “COI Management” to Be Specified in Unified Ethics Code for Epidemiological, Clinical Research
December 18, 2013
- Japan NIH to Be Staffed with 100-Plus Employees from 6 Govt Organizations
December 18, 2013
- MHLW Boots Up Project Team to Spur Clinical Application of Novel Drugs; Paper Due Out in April
December 17, 2013
- Japan Govt OKs Basic Policy for FY2014 Budget; Wording Tweaked in Favor of Healthcare Circles
December 17, 2013
- Diovan Panel to Reopen Discussions on Dec. 25, Hear from 3 Universities
December 17, 2013
- Amount of Funding from Pharma Companies to Healthcare Professionals Totals 466.6 Billion Yen in FY2012
December 17, 2013
- Bill Payers at Chuikyo Oppose Proposal on Evaluation of Generic Drug Use at DPC Hospitals; Subcommittee to Meet Again on Dec. 18
December 16, 2013
- First Generics of Livalo, Glivec Added to NHI Price List: MHLW
December 13, 2013
- No Diovan, Livalo AGs for December Generic NHI Listing
December 13, 2013
- PFSB Begins Discussions Toward Lifting Ban on Subcontracting of Safety Management Tasks
December 12, 2013
- MHLW Notifies Authorities of Expiration Date Extension for Relenza from 7 to 10 Years
December 12, 2013
- 3-Drug Therapy Including Simeprevir for Chronic Hepatitis C to Be Eligible for Medical Expense Assistance: MHLW
December 11, 2013
- September Price Settlement Rate at 73.5%; Low Figure Blamed on Pharmacy Chains
December 10, 2013
- Japan Diet Enacts Bill to Open Door for Online OTC Drug Sales
December 10, 2013
- FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition
December 9, 2013
- Average Drug Price Discrepancy Rate at 8.2%: Health Ministry
December 9, 2013
- PMDA Aims to Solidify Partnerships with Overseas Regulators via February Symposium
December 9, 2013
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…